Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring-Reference-Cited by-同舟云学术

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

Published:2007-05 Issue:5 Volume:6 Page:431-441
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Kappos Ludwig,Bates David,Hartung Hans-Peter,Havrdova Eva,Miller David,Polman Chris H,Ravnborg Mads,Hauser Stephen L,Rudick Richard A,Weiner Howard L,O'Connor Paul W,King John,Radue Ernst Wilhelm,Yousry Tarek,Major Eugene O,Clifford David B

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference89 articles.

1. How many people in the world have multiple sclerosis?;Dean;Neuroepidemiology,1994

2. The natural history of multiple sclerosis: a geographically based study 2: predictive value of the early clinical course;Weinshenker;Brain,1989

3. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial;Neurology,1993

4. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis;Jacobs;Ann Neurol,1996

5. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial;Johnson;Neurology,1995

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies;Neurologic Clinics;2024-02

2. Multiple sclerosis;The Rose and Mackay Textbook of Autoimmune Diseases;2024

3. Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR);Journal of Neurology;2023-04-19

4. Neural stem cell engineering for the treatment of multiple sclerosis;Biomedical Engineering Advances;2022-12

5. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab;Neurological Sciences;2022-02-16